BACKGROUND: We evaluated clinical outcomes of patients with metastatic cervical cancer referred to a Phase I Clinical Trials Program. PATIENTS AND METHODS: We reviewed the electronic medical records of 54 consecutive phase I patients with metastatic cervical cancer over 6.5 years and analyzed the correlation between clinical outcome and potential predictors. RESULTS: All patients had received at least one systemic therapy for metastatic disease before referral. Only two patients declined phase I trial therapy. The median progression-free (PFS) and overall (OS) survivals were 3.6 and 10.6 months, respectively. Patients harboring phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) mutations or phosphatase and tensin homolog loss, and those with more than two sites of metastasis who received more than one prior systemic chemotherapy before the referral had median PFS of 6.7 and 1.8 months, and median OS of 12.6 and 2.9 months, respectively. CONCLUSION: Patients with more than two metastatic sites who had received more than one prior system therapy had dismal outcomes. An aberrant PI3K pathway was frequently identified and associated with favorable outcome, providing a promising target.
BACKGROUND: We evaluated clinical outcomes of patients with metastatic cervical cancer referred to a Phase I Clinical Trials Program. PATIENTS AND METHODS: We reviewed the electronic medical records of 54 consecutive phase I patients with metastatic cervical cancer over 6.5 years and analyzed the correlation between clinical outcome and potential predictors. RESULTS: All patients had received at least one systemic therapy for metastatic disease before referral. Only two patients declined phase I trial therapy. The median progression-free (PFS) and overall (OS) survivals were 3.6 and 10.6 months, respectively. Patients harboring phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) mutations or phosphatase and tensin homolog loss, and those with more than two sites of metastasis who received more than one prior systemic chemotherapy before the referral had median PFS of 6.7 and 1.8 months, and median OS of 12.6 and 2.9 months, respectively. CONCLUSION:Patients with more than two metastatic sites who had received more than one prior system therapy had dismal outcomes. An aberrant PI3K pathway was frequently identified and associated with favorable outcome, providing a promising target.
Authors: Alexander Lin; Sirui Ma; Farrokh Dehdashti; Stephanie Markovina; Julie Schwarz; Barry Siegel; Matthew Powell; Perry Grigsby Journal: Int J Gynecol Cancer Date: 2019-02-09 Impact factor: 3.437
Authors: Ming-Mo Hou; Xiaochun Liu; Jennifer Wheler; Aung Naing; David Hong; Robert L Coleman; Apostolia Tsimberidou; Filip Janku; Ralph Zinner; Karen Lu; Razelle Kurzrock; Siqing Fu Journal: Oncotarget Date: 2014-11-30
Authors: Ming-Mo Hou; Zhijie Wang; Filip Janku; Sarina Piha-Paul; Aung Naing; David Hong; Shannon Westin; Robert L Coleman; Anil K Sood; Apostolia M Tsimberidou; Vivek Subbiah; Jennifer Wheler; Ralph Zinner; Karen Lu; Funda Meric-Bernstam; Siqing Fu Journal: Oncotarget Date: 2016-06-07